JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives

The 2011 approval of ruxolitinib ushered in the Janus kinase (JAK) inhibitor era in the treatment of myelofibrosis (MF), and 2019 saw the US approval of fedratinib. The first therapeutic agents approved by regulatory authorities for MF, these drugs attenuate the overactive JAK-signal transducer and...

Descripción completa

Detalles Bibliográficos
Autores principales: Bose, Prithviraj, Verstovsek, Srdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375176/
https://www.ncbi.nlm.nih.gov/pubmed/32903304
http://dx.doi.org/10.1097/HS9.0000000000000424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375176/
https://www.ncbi.nlm.nih.gov/pubmed/32903304
http://dx.doi.org/10.1097/HS9.0000000000000424

Ejemplares similares